Pharmaceutical composition containing 5-morpholinomethyl-3-(4-chlorobenzylideneamine)-2-oxazolidinone and its use for the treatment of CNS disorders

摘要

PCT No. PCT/PL94/00004 Sec. 371 Date Jul. 26, 1995 Sec. 102(e) Date Jul. 26, 1995 PCT Filed Jan. 24, 1994 PCT Pub. No. WO94/16705 PCT Pub. Date Aug. 4, 1994A method of treating central nervous system diseases and disorders, the diseases and disorders being responsive to drugs possessing psychotropic activity. The method involves administering to a subject suffering from the disease or disorder a therapeutically effective amount of 5-morpholinomethyl-3-(4-chlorobenzylideneamine)-2-oxazolidinone or a pharmaceutically acceptable salt of 5-morpholinomethyl-3-(4-chlorobenzylideneamine)-2-oxazolidinone. The invention also relates to a pharmaceutical composition, the composition having pharmaceutically acceptable carriers and 5-morpholinomethyl-3-(4-chlorobenzylideneamine)-2-oxazolidinone and/or a pharmaceutically acceptable salt of 5-morpholinomethyl-3-(4-chlorobenzylideneamine)-2-oxazolidinone.